Fluocinonide
As of the edition of 20 October 2026, Fluocinonide is a small molecule: marketed, first approved in 1975 (CH); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Lidex
- First approved
- 4 February 1975 (CH)
- Approvals on record
- 13 in 4 regions
- Holder of the most recent approval
- Bausch Health; 5 holders in all
- Registered trials
- 11, 2 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Inherited and neonatal; Cancer; Blood and lymph; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Fluocinonide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 1 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 4 | 3 | 2 | 1 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 1995 to now |
| Alvogen | Acquired holder | 2021 to now |
| Sun Pharma | Acquired holder | 2025 to now |
| Medicis Pharmaceutical | Earlier holder |